Drugs / Combined Diphtheria-Tetanus-recombinant acellular pertussis (DTaP) vaccine

Follow last change May 2022 re-read 3 minutes ago

Combined Diphtheria-Tetanus-recombinant acellular pertussis (DTaP) vaccine

Developed for: pertussis
Investigated by: BioNet-Asia Co., Ltd. · Mahidol University · National Science and Technology Development Agency, Thailand

today NCT07213089 · Ph 2/3

202120222023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2/3	NCT07213089	Jul 2020 → Apr 2022	pertussis	BioNet-Asia Co., Ltd.	Completed	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	Combined Diphtheria-Tetanus-recombinant acellular pertussis (DTaP) vaccine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT07213089 ↗
Modality	Vaccine	“a new recombinant pediatric DTaP vaccine (DTaPgen)” NCT07213089 ↗